C12N 2795/10364
By serial passage
Official title: by serial passage
C12N2795/10364 (By serial passage) appears on 4 US grants and 5 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 5
- Assignees
- 4
- Inventors
- 3
- Latest grant
- 22 Sep 1998
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 2 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Bacteriophage genotypically modified to delay inactivations by the host defense system22 Sep 1998US 5,811,093 AExponential Biotherapies, Inc.
- Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system together with an antibiotic16 Jun 1998US 5,766,892 AExponential Biotherapies, Inc.
- Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system18 Nov 1997US 5,688,501 AExponential Biotherapies, Inc.
- Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system26 Aug 1997US 5,660,812 AExponential Biotherapies, Inc.
- Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system24 Mar 2005US 2005/0063957 A1
- Antibacterial therapy with bacteriophage genotypically modified to delay inactiovation by the host defense system19 Aug 2004US 2004/0161411 A1
- Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system6 Feb 2003US 2003/0026785 A1
- Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system22 Nov 2001US 2001/0043917 A1
- Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system4 Oct 2001US 2001/0026795 A1Exponential Biotherapies, Inc.
Most cited
By later US patents
- Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system48US 5,688,501 AExponential Biotherapies, Inc. · 1997
- Bacteriophage genotypically modified to delay inactivations by the host defense system31US 5,811,093 AExponential Biotherapies, Inc. · 1998
- Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system together with an antibiotic18US 5,766,892 AExponential Biotherapies, Inc. · 1998
- Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system15US 5,660,812 AExponential Biotherapies, Inc. · 1997